Form 4: MPM BioVentures Sells Shares in Entrada Therapeutics

MPM BioVentures and related entities sold a total of 44,722 shares of Entrada Therapeutics (TRDA) across two days, reducing their holdings.

Summary

• MPM BioVentures and associated entities, including several limited partnerships and LLCs, sold shares of Entrada Therapeutics (TRDA) on December 10th and 11th, 2024.
• On December 10th, 22,935 shares were sold at a weighted average price of $20.77 per share, with individual sale prices ranging from $20.356 to $21.315.
• On December 11th, 21,787 shares were sold at a weighted average price of $20.23 per share, with individual sale prices ranging from $20.01 to $20.595.
• The sales were executed by multiple entities within the MPM BioVentures group, including MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2018, L.P., MPM BioVentures 2018 (B), L.P., and MPM Asset Management Investors BV2018 LLC.
• Following these transactions, the total indirect holdings of the MPM BioVentures group decreased to 4,381,062 shares.

Sentiment

Score: 3

Explanation: The document indicates a reduction in holdings by a major investor, which is generally viewed negatively by the market. This suggests a potential lack of confidence or a shift in investment strategy by MPM BioVentures.

Negatives

• The sales by MPM BioVentures indicate a reduction in their stake in Entrada Therapeutics.

Risks

• Continued selling pressure from MPM BioVentures could negatively impact the share price of Entrada Therapeutics.
• The sales may indicate a change in MPM BioVentures' investment strategy or outlook for Entrada Therapeutics.

Industry Context

Form 4 filings are a standard part of regulatory compliance for significant shareholders and insiders, providing transparency into their trading activities. This filing indicates a reduction in holdings by a major investor in the biotechnology sector.

Comparison to Industry Standards

• Form 4 filings are a common occurrence for publicly traded companies, particularly in the biotech sector where venture capital firms often hold significant stakes.
• The size of the sale, while notable, is not unusual for a major shareholder adjusting their portfolio.
• Comparable companies with similar venture capital backing would also have similar filings when significant share sales occur.

Stakeholder Impact

• The share sales could negatively impact the share price of Entrada Therapeutics, affecting current shareholders.
• The reduction in holdings by a major investor may raise concerns among other investors.

Key Dates

Keywords

Entrada Therapeutics, MPM BioVentures, share sale, insider trading, TRDA, equity